Trials / Completed
CompletedNCT02560610
Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma
The Effect of OC000459 on Eosinophilic Airway Inflammation and Asthma Control in Subjects With Refractory Eosinophilic Asthma: a Randomised, Double-blind, Placebo Controlled Trial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Chiesi Farmaceutici S.p.A. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim is to study the effect of OC000459 on eosinophilic airway inflammation and asthma control in subjects with severe, refractory eosinophilic asthma.
Detailed description
At week 12 subjects not on oral corticosteroids (OCS) will complete the treatment period and return after 4 weeks for final follow up visit. Those subjects who were taking OCS at baseline will continue for a maximum of 12 additional weeks, double blind period during which their current OCS treatment will be titrated down according to their clinical response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OC000459 | |
| DRUG | Placebo |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2018-08-02
- Completion
- 2018-08-02
- First posted
- 2015-09-25
- Last updated
- 2019-08-29
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02560610. Inclusion in this directory is not an endorsement.